Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
|Articles|May 15, 2017
- Pharmaceutical Technology-05-15-2017
- Volume 2017 eBook
- Issue 1
Parallel Processing
Author(s)Agnes Shanley
Samsung BioLogics’ aggressive growth strategy begs the question: Are there lessons that US and European pharma might still learn from the electronics industry?
Advertisement
A look at how engineering-led companies from outside pharma are transforming biopharmaceutical contract services, and an interview with Samsung BioLogics’ vice president and head of business development, James Park, on the company’s history, culture, and plans.
Articles in this issue
over 9 years ago
Clean, Disinfect, and Validateover 9 years ago
Kill the Bioburden, Not the Biological Indicatorover 9 years ago
Ensuring the Biological Integrity of Raw Materialsover 9 years ago
Getting Biopharmaceutical Tech Transfer Right the First Timeover 9 years ago
Case Study: Retrofitting Two New High-Purity Water Systemsover 9 years ago
Single-Use Bioreactors Have Reached the Big Timeover 9 years ago
Cost Considerations Drive Lean Technology in BiomanufacturingAdvertisement
Related to this article
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
AAPS PharmSci 360 2026: Spray Drying and ASD
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5